SK bioscience, a South Korea-based innovative vaccine and biotech company committed to promoting human health from prevention to cure across the globe, has officially decided to initiate the establishment of the Songdo Global Research & Process Development Centre (The R&PD Centre).

The establishment of the R&PD Centre will be proceeded on a 30,413.8㎡ site in Songdo, Republic of Korea with a total investment of $261 million (325.7 billion KRW), including the previous investment of $33 million (41.9 billion KRW). 

Once the establishment of the R&PD Centre is completed in the first half of 2025, the headquarters and the research and development (R&D) centre currently located in Pangyo will move to Songdo area. 

SK bioscience aims to secure the newest technologies covering the entire process from basic research to commercial manufacturing and to ultimately create a global vaccine ecosystem to preemptively respond to new infectious diseases through the establishment.

To achieve the goal, SK bioscience plans to operate the 'Open Lab' in the R&PD Centre to strengthen a global vaccine network. The Open Lab will be utilised as a joint research space for international organisations and biopharmaceutical companies around the world to develop new vaccines together with SK bioscience.

SK bioscience will also secure the advanced BSL-3 (Biological Safety Level) research facilities to further strengthen its own vaccine pipeline.

A pilot plant, a small-scale test facility utilised before commercialising a new method or a product, will be established at the R&PD. The plant will be designed as a cGMP-level production facility, the highest demanding standard worldwide.

Since the plant can produce samples for non-clinical, clinical, and commercial-scale, SK bioscience will accelerate expanding its new pipeline through synergy with 'L-HOUSE', a vaccine manufacturing facility located in Andong area.